OCTOBER 2023LIFE SCIENCES REVIEW 19CXO INSIGHTSTHE REVOLUTIONARY POWER OF CELL AND GENE THERAPIESIn your experience as a managing director at Eurofins, what would you say are some of the recent changes you witnessed regarding the implementation and use of technology?The core of my work is linked to the world of cell and gene therapies. It is that part of life sciences where innovation is important and is something that the industry is proactively looking for. Cell and gene therapies are innovative medicine, as they can provide life-changing solutions and ultimately be a physician's weapon. However, there is currently no clear model for those. We have autologous and allogeneic cells, fresh and frozen cells. These are pieces of the puzzle that can make these products simpler from a manufacturing perspective or, more importantly, more sustainable from an industry perspective. Sustainability is the key element for manufacturing cell and gene therapies. How important is collaboration when it comes to developing and researching new medications?Historically, collaboration is how the front runners in cell and gene therapy were developed. Identifying the right strategy or the right target for cell and gene therapy and medicine was a major priority. It is vital that young startups, biotech organizations, and other companies with fresh portfolios can leverage collaboration. In the early days, we witnessed something that reflected true collaboration. In today's world, it is about recognizing the value that each team Stefano Baila Stefano Baila, Managing Director, Biologics, Eurofins
< Page 9 | Page 11 >